Cellivery Therapeutics Inc. (268600)
KRX SM KRX SM Primary Summary
268600 Chart
Cellivery Therapeutics Inc. (268600) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cellivery Therapeutics Inc. ever had a stock split?
Cellivery Therapeutics Inc. Profile
| - Industry | - Sector | Dr. Daewoong Jo Ph.D. CEO | KRX SM Exchange | KR7268600004 ISIN |
| South Korea Country | 4 Employees | - Last Dividend | 25 Jul 2022 Last Split | - IPO Date |
Overview
Cellivery Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative therapeutic drugs aimed at addressing the challenges of life-threatening diseases. With a focus on cancer, inflammation, metabolic disorders, and neurodegenerative diseases, Cellivery Therapeutics endeavors to bring new solutions to the forefront of medicine. Established in 2014 and headquartered in Seoul, South Korea, the company leverages cutting-edge therapeutic molecule systemic delivery technology to create a diversified pipeline of small molecule, antibody, and vaccine drugs. This technology represents the cornerstone of their research and development efforts, projecting Cellivery Therapeutics as a significant player in the fight against some of the most challenging health issues facing the world today.
Products and Services
- Small Molecule Drugs
These are chemically synthesized compounds that have the potential to modulate biological targets implicated in various diseases. Cellivery Therapeutics is leveraging its proprietary delivery technology to improve the bioavailability and therapeutic efficacy of these small molecules, aiming to provide targeted treatments for conditions such as cancer and metabolic diseases.
- Antibody Drugs
Cellivery Therapeutics develops antibodies designed to specifically bind to and inhibit the activity of proteins involved in disease pathways. Their focus is on creating monoclonal antibodies for the treatment of inflammatory and neurodegenerative diseases, utilizing their systemic delivery platform to enhance penetration and efficacy.
- Vaccine Drugs
Vaccines are a core area of research and development at Cellivery Therapeutics, with the aim of preventing or treating life-threatening diseases. By employing their therapeutic molecule systemic delivery technology, they are working on vaccine candidates that could offer new hope against difficult-to-treat conditions, including certain types of cancer and neurodegenerative diseases.
